Lobbying Information
Subject Matters
- Budget
- Economic Development
- Environment
- Health
- Industry
- Intellectual Property
- Internal Trade
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
Legislative Proposal, Bill or Resolution, Policies or Program
- Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
- Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.
- Food and Drugs Act: Delays in product approvals and changes to existing products.
- Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
- Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
Legislative Proposal, Bill or Resolution, Regulation
- Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
Policies or Program
- COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
- Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
- Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
- Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
- Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
- Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
Regulation
- Communication to officials on labelling and product monographs.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Immigration, Refugees and Citizenship Canada (IRCC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Johnson & Johnson (Canada) Inc. is a subsidiary of US based Johnson & Johnson and is focused on the manufacture, development and sale of a broad range of products in the healthcare field, including medical devices and digital and robotic solutions and services. Johnson and Johnson (Canada) Inc. has no subsidiary companies, although another entity, Janssen Inc., which is also registered to lobby federally, may have a direct interest in its lobbying.
Responsible officer name and position during the period of this registration
James Brodie,
General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
200 Whitehall Drive
Markham, ON L3R 0T5
Canada
Telephone number:
905-946-2013
Parent Company Information
- Johnson & Johnson / Johnson & Johnson
-
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States of America
Subsidiary Beneficiary Information
Johnson & Johnson (Canada) Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- James Brodie,
General Manager |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Lesia Babiak,
Head, Worldwide Government Affairs & Policy (Canada) |
No public offices held
- Geneviève Lavertu,
Director, Government Affairs and Policy – Medical Technology |
Public offices held
